Weekly injections of the GLP-1 semaglutide reduce alcohol consumption in patients with obesity seeking treatment for alcohol ...

Research indicates semaglutide can significantly decrease alcohol consumption and cravings in individuals with comorbid ...

Novo Nordisk (NYSE:NVO) is exploring semaglutide as a potential treatment for alcohol use disorder, expanding beyond its current uses in diabetes and obesity. The company has also begun Phase 1 trials ...

In a placebo-controlled randomized trial, adults with obesity and alcohol use disorder had a greater drop in heavy drinking ...

National Institutes of Health (NIH) released the following: A team of National Institutes of Health (NIH) scientists and ...

Once-weekly semaglutide was tied to a reduction in heavy drinking days among adults with obesity and alcohol use disorder, ...

Compared with placebo, semaglutide achieved larger reductions in heavy-drinking days (−41.1 vs −26.4 percentage points) and ...

A landmark clinical trial has found that semaglutide, a GLP-1 receptor agonist widely used for obesity, significantly reduced heavy drinking days in adults with alcohol use disorder (AUD) and obesity ...

April 30, 2026 expert reaction to an RCT for semaglutide in patients with alcohol use disorder and comorbid obesity . A randomised controlled trial published in The Lancet looks a ...